Shares of Exactech, Inc. (NASDAQ:EXAC) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Brokers have set a 1-year consensus target price of $32.00 for the company and are expecting that the company will post $0.33 earnings per share for the current quarter, according to Zacks. Zacks has also given Exactech an industry rank of 114 out of 265 based on the ratings given to its competitors.

A number of research firms recently issued reports on EXAC. TheStreet raised shares of Exactech from a “c+” rating to a “b” rating in a research report on Tuesday, April 25th. Zacks Investment Research raised shares of Exactech from a “sell” rating to a “hold” rating in a research report on Tuesday, April 25th.

In other Exactech news, CFO Joel C. Phillips sold 7,610 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $30.71, for a total value of $233,703.10. Following the completion of the sale, the chief financial officer now owns 99,907 shares of the company’s stock, valued at $3,068,143.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William B. Locander sold 988 shares of the stock in a transaction that occurred on Wednesday, May 31st. The shares were sold at an average price of $30.34, for a total transaction of $29,975.92. Following the completion of the sale, the director now directly owns 8,555 shares of the company’s stock, valued at approximately $259,558.70. The disclosure for this sale can be found here. 28.30% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the stock. Kirr Marbach & Co. LLC IN increased its stake in shares of Exactech by 1.2% in the first quarter. Kirr Marbach & Co. LLC IN now owns 10,760 shares of the medical equipment provider’s stock valued at $271,000 after buying an additional 125 shares during the period. American International Group Inc. increased its stake in shares of Exactech by 7.1% in the first quarter. American International Group Inc. now owns 6,423 shares of the medical equipment provider’s stock valued at $162,000 after buying an additional 424 shares during the period. ClariVest Asset Management LLC increased its stake in shares of Exactech by 5.4% in the first quarter. ClariVest Asset Management LLC now owns 10,908 shares of the medical equipment provider’s stock valued at $275,000 after buying an additional 554 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Exactech by 7.7% in the first quarter. Goldman Sachs Group Inc. now owns 36,617 shares of the medical equipment provider’s stock valued at $923,000 after buying an additional 2,612 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Exactech by 13.3% in the first quarter. Bank of America Corp DE now owns 33,912 shares of the medical equipment provider’s stock valued at $855,000 after buying an additional 3,981 shares during the period. 63.97% of the stock is owned by institutional investors.

Shares of Exactech (NASDAQ:EXAC) opened at 30.60 on Tuesday. The firm has a market capitalization of $437.95 million, a PE ratio of 1275.00 and a beta of 1.03. The firm’s 50 day moving average is $30.62 and its 200-day moving average is $27.56. Exactech has a 12 month low of $22.20 and a 12 month high of $31.90.

Exactech (NASDAQ:EXAC) last posted its earnings results on Tuesday, April 25th. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.03. The firm had revenue of $69.48 million during the quarter, compared to the consensus estimate of $67.05 million. Exactech had a net margin of 0.13% and a return on equity of 7.27%. The company’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.31 EPS. On average, analysts expect that Exactech will post $1.30 EPS for the current fiscal year.

WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/07/18/exactech-inc-exac-receives-consensus-rating-of-strong-buy-from-brokerages.html.

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Get a free copy of the Zacks research report on Exactech (EXAC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.